Galapagos' Strategic Shift: Betting On CAR-T And A Fresh Start (Rating Upgrade)
Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...
manilatimes7h
T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of Directors
T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) ...
Groundbreaking one-time £297,000 cancer treatment offered on NHS
Hundreds of people with aggressive blood cancer will be offered a groundbreaking one-off personalised therapy that reprogrammes their immune system to fight the disease.The treatment has a list price ...
People with blood cancer to benefit from innovative new treatment on the NHS
Hundreds of people in England with aggressive blood cancer are set to benefit from an innovative new treatment that reprogrammes a patient’s own immune cells to fight the disease after it was ...
Disount To Net Cash For A Promising CAR-T Company
Galapagos NV’s split could unlock value despite short-term share decline. Learn why GLPG stock’s strategic focus offers ...
Medpage Today on MSN22h
Neuroblastoma Patient Still in Remission 18 Years After CAR-T Infusion
Among 19 neuroblastoma patients treated with CAR T-cell therapy, eight survived more than 5 years after infusion, including ...
The Lancet20h
Direct oral anticoagulants for cerebral venous thrombosis
Cerebral venous thrombosis is a rare but potentially life-threatening condition that is particularly prevalent in young women (ie, mean age 44 years) and accounts for 0·5–3% of all strokes. The ...